GemOx

GemOx or GEMOX is an acronym for one of the chemotherapy regimens used in the treatment of relapsed or primary refractory non-Hodgkin lymphoma and Hodgkin lymphoma.

When combined with Rituximab it is called R-GemOx, R-GEMOX or GemOx-R, GEMOX-R.

The [R]-GemOx regimen consists of:

1. Rituximab - anti-CD20 monoclonal antibody that has the ability to kill both normal and malignant B cells;
2. Gemcitabine - an antimetabolite;
3. Oxaliplatin - a platinum-based alkylating antineoplastic agent. ^{[1] [2]}

Dosing regimen

Drug	Dose	Mode	Days
Rituximab	375 mg/m2	IV infusion	Day 1
Gemcitabine	1000 mg/m2	IV infusion in 500 ml normal saline with the speed of 10 mg/m2/min	Day 2
Oxaliplatin	100 mg/m2	IV infusion over 2hrs	Day 2

References

1. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory / relapsing diffuse large-cell lymphoma: a phase II study
2. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy